These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

778 related articles for article (PubMed ID: 30188416)

  • 21. Diagnostic utility of metabolic parameters on FDG PET/CT for lymph node metastasis in patients with cN2 non-small cell lung cancer.
    Nakanishi K; Nakamura S; Sugiyama T; Kadomatsu Y; Ueno H; Goto M; Ozeki N; Fukui T; Iwano S; Chen-Yoshikawa TF
    BMC Cancer; 2021 Sep; 21(1):983. PubMed ID: 34474680
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic value of total lesion glycolysis by 18F-FDG PET/CT in surgically resected stage IA non-small cell lung cancer.
    Park SY; Cho A; Yu WS; Lee CY; Lee JG; Kim DJ; Chung KY
    J Nucl Med; 2015 Jan; 56(1):45-9. PubMed ID: 25525185
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic value of volumetric parameters measured by F-18 FDG PET/CT in surgically resected non-small-cell lung cancer.
    Kim K; Kim SJ; Kim IJ; Kim YS; Pak K; Kim H
    Nucl Med Commun; 2012 Jun; 33(6):613-20. PubMed ID: 22407127
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic value of SUVmax and metabolic tumor volume on 18F-FDG PET/CT in early stage non-small cell lung cancer patients without LN metastasis.
    Yoo IeR; Chung SK; Park HL; Choi WH; Kim YK; Lee KY; Wang YP
    Biomed Mater Eng; 2014; 24(6):3091-103. PubMed ID: 25227018
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Optimal FDG PET/CT volumetric parameters for risk stratification in patients with locally advanced non-small cell lung cancer: results from the ACRIN 6668/RTOG 0235 trial.
    Salavati A; Duan F; Snyder BS; Wei B; Houshmand S; Khiewvan B; Opanowski A; Simone CB; Siegel BA; Machtay M; Alavi A
    Eur J Nucl Med Mol Imaging; 2017 Nov; 44(12):1969-1983. PubMed ID: 28689281
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk Factors for Predicting Occult Lymph Node Metastasis in Patients with Clinical Stage I Non-small Cell Lung Cancer Staged by Integrated Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography.
    Kaseda K; Asakura K; Kazama A; Ozawa Y
    World J Surg; 2016 Dec; 40(12):2976-2983. PubMed ID: 27456499
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Application of novel quantitative techniques for fluorodeoxyglucose positron emission tomography/computed tomography in patients with non-small-cell lung cancer.
    Wang D; Koh ES; Descallar J; Pramana A; Vinod SK; Ho Shon I
    Asia Pac J Clin Oncol; 2016 Dec; 12(4):349-358. PubMed ID: 27550522
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic Value of Metabolic Parameters of Metastatic Lymph Nodes on
    Jin F; Qu B; Fu Z; Zhang Y; Han A; Kong L; Yu J
    Clin Lung Cancer; 2018 Jan; 19(1):e101-e108. PubMed ID: 28690012
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic Value of the Volumetric Parameters of Dual-Time-Point
    Okazaki E; Seura H; Hasegawa Y; Okamura T; Fukuda H
    AJR Am J Roentgenol; 2019 Dec; 213(6):1366-1373. PubMed ID: 31509426
    [No Abstract]   [Full Text] [Related]  

  • 30. Comparison of prognostic values of primary tumor and nodal
    Lim CH; Hyun SH; Moon SH; Cho YS; Choi JY; Lee KH
    Eur Radiol; 2019 Oct; 29(10):5288-5297. PubMed ID: 30899978
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The maximum standardized uptake value of fluorodeoxyglucose positron emission tomography of the primary tumour is a good predictor of pathological nodal involvement in clinical N0 non-small-cell lung cancer.
    Miyasaka Y; Suzuki K; Takamochi K; Matsunaga T; Oh S
    Eur J Cardiothorac Surg; 2013 Jul; 44(1):83-7. PubMed ID: 23233074
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic value of metabolic tumor volume of pretreatment
    Kumasaka S; Nakajima T; Arisaka Y; Tokue A; Achmad A; Fukushima Y; Shimizu K; Kaira K; Higuchi T; Tsushima Y
    BMC Med Imaging; 2018 Nov; 18(1):46. PubMed ID: 30477476
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Significance of
    Kim E; Wu HG; Keam B; Kim TM; Kim DW; Paeng JC; Kim HJ; Chang JH
    Clin Lung Cancer; 2019 Jan; 20(1):e9-e23. PubMed ID: 30266585
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic impact of the
    Goksel S; Cengiz A; Ozturk H; Yurekli Y
    J Cancer Res Ther; 2021; 17(4):925-930. PubMed ID: 34528543
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Primary tumor standardized uptake value (SUVmax) measured on
    Hui Z; Wei F; Ren H; Xu W; Ren X
    J Cancer Res Clin Oncol; 2020 Oct; 146(10):2595-2605. PubMed ID: 32494919
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Total metabolic tumor volume by 18F-FDG PET/CT for the prediction of outcome in patients with non-small cell lung cancer.
    Pellegrino S; Fonti R; Mazziotti E; Piccin L; Mozzillo E; Damiano V; Matano E; De Placido S; Del Vecchio S
    Ann Nucl Med; 2019 Dec; 33(12):937-944. PubMed ID: 31612416
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FDG PET/CT metabolic tumor volume and total lesion glycolysis predict prognosis in patients with advanced lung adenocarcinoma.
    Chung HW; Lee KY; Kim HJ; Kim WS; So Y
    J Cancer Res Clin Oncol; 2014 Jan; 140(1):89-98. PubMed ID: 24194352
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predictive value of metabolism and its heterogeneity parameters measured by preoperative
    Yang Z; Liu Z; Zhang S; Qiu B; Chai H; Wei L; Li N; He Z; Luo Y; Wei H; Gan M; Xiao G
    Hell J Nucl Med; 2024; 27(2):78-84. PubMed ID: 39097804
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The value on SUV-derived parameters assessed on
    Liao X; Liu M; Li S; Huang W; Guo C; Liu J; Xiong Y; Zhang J; Fan Y; Wang R
    BMC Med Imaging; 2023 Apr; 23(1):49. PubMed ID: 37020286
    [TBL] [Abstract][Full Text] [Related]  

  • 40. FDG PET/CT texture analysis for predicting the outcome of lung cancer treated by stereotactic body radiation therapy.
    Lovinfosse P; Janvary ZL; Coucke P; Jodogne S; Bernard C; Hatt M; Visvikis D; Jansen N; Duysinx B; Hustinx R
    Eur J Nucl Med Mol Imaging; 2016 Jul; 43(8):1453-60. PubMed ID: 26830299
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 39.